butylhydroxybutylnitrosamine and Cholecystitis, Acute

butylhydroxybutylnitrosamine has been researched along with Cholecystitis, Acute in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Eriksson, P; Foth, M; Ismail, NFB; Iwata, T; Knowles, MA; Kung, JSC; Salmond, JM; Sansom, OJ; Sjödahl, G; Tomlinson, D	1

Other Studies

1 other study(ies) available for butylhydroxybutylnitrosamine and Cholecystitis, Acute

Article	Year
FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation. The Journal of pathology, 2018, Volume: 246, Issue:3 Topics: Animals; Butylhydroxybutylnitrosamine; Cell Transformation, Neoplastic; Cholecystitis, Acute; Disease Models, Animal; Disease Progression; Female; Genetic Predisposition to Disease; Lymphocytes; Male; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neutrophil Infiltration; Neutrophils; Phenotype; Receptor, Fibroblast Growth Factor, Type 3; Time Factors; Tumor Microenvironment; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium	2018

Article

Year

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.

The Journal of pathology, 2018, Volume: 246, Issue:3

Topics: Animals; Butylhydroxybutylnitrosamine; Cell Transformation, Neoplastic; Cholecystitis, Acute; Disease Models, Animal; Disease Progression; Female; Genetic Predisposition to Disease; Lymphocytes; Male; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neutrophil Infiltration; Neutrophils; Phenotype; Receptor, Fibroblast Growth Factor, Type 3; Time Factors; Tumor Microenvironment; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium

2018